Instadose Pharma Corp. (INSD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInstadose Pharma Corp. (INSD) trades at $0.0001. Instadose Pharma Corp. focuses on the cultivation, processing, and global distribution of medical-grade cannabinoid oil. Founded in 2017, the company aims to establish a presence in the burgeoning medical cannabis market. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for INSD: INSD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Instadose Pharma Corp. (INSD) Healthcare & Pipeline Overview
Instadose Pharma Corp. cultivates, processes, and distributes medical-grade cannabinoid oil globally, operating within the specialty and generic drug manufacturing sector. The company faces significant competition and regulatory hurdles in the evolving cannabis market, with a focus on establishing reliable supply chains.
What Is the Investment Thesis for INSD?
Instadose Pharma Corp. presents a high-risk, high-reward investment opportunity within the rapidly evolving medical cannabis sector. The company's focus on medical-grade cannabinoid oil positions it to capitalize on the increasing acceptance and legalization of cannabis for medicinal purposes. However, the company's small size and limited resources, indicated by its market capitalization of $0.00B and only two employees, pose significant challenges. Key value drivers include securing regulatory approvals in key markets, establishing reliable supply chains, and forming strategic partnerships with pharmaceutical companies. Growth catalysts include the expansion of medical cannabis legalization globally and the development of new cannabinoid-based therapies. Potential risks include intense competition from established players, fluctuating cannabinoid prices, and evolving regulatory frameworks.
Based on FMP financials and quantitative analysis
INSD Key Highlights
Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -0.01 suggests the company is not currently profitable.
- Beta of -401.63 indicates extreme volatility and a negative correlation with the market.
- The company's focus on medical-grade cannabinoid oil aligns with the growing demand for cannabis-based therapies.
- Based in Canada, Instadose Pharma benefits from a relatively progressive regulatory environment for cannabis.
Who Are INSD's Competitors?
INSD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $5.03 | +56.21% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $20.9M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| TXMD TherapeuticsMD, Inc. | $2.08 | +1.22% | $24.0M | — |
| CPHI CPHI | $0.67 | +1.57% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INSD's Key Strengths?
Focus on medical-grade cannabinoid oil.
- Potential for early mover advantage in emerging markets.
- Strategic location in Canada with established cannabis regulations.
What Are INSD's Weaknesses?
Small size and limited resources.
- Dependence on regulatory approvals.
- Limited brand recognition.
What Are the Key Risks for INSD?
Financial-distress signal — its Altman Z-Score of -5.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players could limit market share.
- Fluctuating cannabinoid prices could impact profitability.
- Evolving regulatory frameworks could create uncertainty and increase compliance costs.
- Limited financial resources may hinder growth and expansion.
- Dependence on a small number of customers could create vulnerability.
What Are INSD's Competitive Advantages?
- Focus on medical-grade cannabinoid oil provides a degree of differentiation.
- Early mover advantage in establishing relationships with pharmaceutical companies (potential).
- Proprietary cultivation and extraction techniques (if any, not specified in data).
What Does INSD Do?
Instadose Pharma Corp., established in 2017, is a Canadian company focused on the production and distribution of medical-grade cannabinoid oil. The company's operations encompass the entire value chain, from growing and cultivation to processing and global distribution. Instadose Pharma aims to supply pharmaceutical companies and researchers with high-quality cannabinoid oil for various medical applications. Based in Burlington, Canada, the company is strategically positioned to serve both domestic and international markets. The company's core business revolves around cultivating various strains of cannabis, extracting cannabinoid oils, and ensuring product quality through rigorous testing and adherence to regulatory standards. Instadose Pharma's success hinges on its ability to navigate the complex regulatory landscape governing the production and distribution of medical cannabis, while also establishing strong relationships with key players in the pharmaceutical industry. The company's long-term vision involves expanding its product portfolio and geographic reach to become a leading global supplier of medical-grade cannabinoid oil. With only two employees, Instadose Pharma is in the early stages of development.
What Products and Services Does INSD Offer?
- Cultivates medical-grade cannabis.
- Processes cannabis to extract cannabinoid oil.
- Distributes cannabinoid oil to pharmaceutical companies.
- Focuses on global distribution of medical cannabis products.
- Aims to provide high-quality cannabinoid oil for medical applications.
- Operates within the regulated medical cannabis industry.
- Seeks to expand its product portfolio and geographic reach.
How Does INSD Make Money?
- Generates revenue through the sale of medical-grade cannabinoid oil.
- Focuses on supplying pharmaceutical companies and researchers.
- Aims to establish long-term contracts with key customers.
What Industry Does INSD Operate In?
Instadose Pharma Corp. operates within the rapidly expanding medical cannabis industry. The industry is characterized by intense competition, evolving regulatory frameworks, and fluctuating prices. Instadose Pharma competes with both large pharmaceutical companies and smaller cannabis producers. The company's success depends on its ability to differentiate itself through product quality, regulatory compliance, and strategic partnerships. Companies like Aurora Cannabis and Canopy Growth are major players in the Canadian cannabis market, while others such as Arena Pharmaceuticals are focused on cannabinoid-based drug development.
Who Are INSD's Key Customers?
- Pharmaceutical companies developing cannabinoid-based therapies.
- Researchers studying the medical applications of cannabis.
- Distributors of medical cannabis products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Instadose Pharma Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Burlington, CA. The company is led by CEO Antonio Rocco Franchino. INSD has traded publicly since 2020.
Financial Health
Instadose Pharma Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.65 places it in the distress zone, a signal of elevated financial risk.
INSD Latest News
No recent news available for INSD.
INSD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for INSD.
Price Targets
Wall Street price target analysis for INSD.
INSD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for INSD; grades run from A+ (80-100) to F (below 30).
Leadership: Antonio Rocco Franchino
CEO
Antonio Rocco Franchino is the CEO of Instadose Pharma Corp. His background includes managing the company's operations with a team of only two employees. His leadership is focused on guiding the company through the complex regulatory landscape of the medical cannabis industry and establishing strategic partnerships to drive growth.
Track Record: Due to the limited information available, it is difficult to assess Antonio Rocco Franchino's track record. Key milestones under his leadership include navigating the initial stages of establishing Instadose Pharma Corp. in the medical cannabis market. Further information is needed to evaluate his strategic decisions and their impact on the company's performance.
INSD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Instadose Pharma Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, increasing the risk of fraud and manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in INSD.
- Low liquidity can lead to price volatility and difficulty in trading shares.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- The company's small size and limited resources pose significant operational challenges.
- The evolving regulatory landscape of the cannabis industry adds uncertainty.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor before investing.
- Focus on medical-grade cannabinoid oil suggests a commitment to quality.
- Based in Canada, which has a relatively well-established cannabis regulatory framework.
- Company has been in operation since 2017, indicating some level of operational stability.
INSD Healthcare Stock FAQ
What do analysts say about INSD stock?
As of March 18, 2026, there is no available analyst coverage for Instadose Pharma Corp. (INSD). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Instadose Pharma Corp.
- OTC Other listing indicates higher risk.